PFE - Pfizer Inc.

NYSE - NYSE Delayed Price. Currency in USD
Show:
Balance sheet
Cash flow
Annual

Income statement

All numbers in thousands
Breakdown
ttm
31/12/2022
31/12/2021
31/12/2020
31/12/2019
Total revenue
100,330,000
100,330,000
81,288,000
41,908,000
51,750,000
Cost of revenue
34,344,000
34,344,000
30,821,000
8,692,000
10,219,000
Gross profit
65,986,000
65,986,000
50,467,000
33,216,000
41,531,000
Operating expenses
Research development
11,428,000
11,428,000
13,829,000
9,405,000
8,650,000
Selling general and administrative
13,677,000
13,677,000
12,703,000
11,615,000
14,350,000
Total operating expenses
28,714,000
28,714,000
30,232,000
24,456,000
27,610,000
Operating income or loss
37,272,000
37,272,000
20,235,000
8,760,000
13,921,000
Interest expense
1,238,000
1,238,000
1,291,000
1,449,000
1,574,000
Total other income/expenses net
-1,556,000
-1,555,000
5,331,000
113,000
5,108,000
Income before tax
34,729,000
34,729,000
24,311,000
7,497,000
17,682,000
Income tax expense
3,328,000
3,328,000
1,852,000
477,000
1,384,000
Income from continuing operations
31,401,000
31,401,000
22,459,000
7,021,000
16,298,000
Net income
31,372,000
31,372,000
21,979,000
9,616,000
16,273,000
Net income available to common shareholders
31,372,000
31,372,000
21,979,000
9,616,000
16,273,000
Basic EPS
-
-
3.92
1.65
2.88
Diluted EPS
-
-
3.85
1.63
2.82
Basic average shares
-
-
5,601,000
5,555,000
5,569,000
Diluted average shares
-
-
5,708,000
5,632,000
5,675,000
EBITDA
-
39,576,000
29,302,000
12,382,000
23,866,000